

Ovarian Cancer End Points Workshop
April 26, 2006
North Bethesda Marriott – Bethesda, MD

Panelists

Susan G. Arbuck, MD

Schering-Plough Research Inst.
Kenilworth, NJ 07033
Med Onc, Industry Rep

Karen Basen-Engquist, PhD

Assoc Prof., Behavioral Science
MD Anderson Cancer Ctr
Houston, TX 77030
PRO Expert

Robert C. Bast, MD

Translational Research
MD Anderson Cancer Ctr
Houston, TX 77030-4009
Med Onc/Hem

Mark F. Brady, PhD

Gynecologic Oncology Group (GOG)
Statistical & Data Center
Buffalo, NY 14263
Biostats/Epid

Marc Buyse, ScD

Department of Clinical Research &
Biostatistics
Institut National du Cancer - INCa
Paris, France
Biostats

Elizabeth Eisenhauer, MD

NCI-Canada Clinical Trials Grp
Cancer Research Inst.
Kingston, ONT Canada
Med Onc/Hem, Int Med

Ralph S. Freedman, MD, PhD

MD Anderson Cancer Ctr
Gyn Dept
Houston, TX 77030-4095
Gyn Onc

Stacy R. Nerenstone, MD

Oncology Assoc, PC
Gray Cancer Ctr
Hartford, CT 06106-2527
Med Onc

Robert F. Ozols, MD, PhD

Fox Chase Cancer Ctr
Philadelphia, PA 19111-2497
Med Onc

Peter G. Rose, MD

Cleveland Clinic Foundation
Cleveland, OH 44195
Gyn Onc

Gordon J.S. Rustin, MD

Mount Vernon Cancer Ctr
Dept of Medical Onc
Middlesex, England
Med Onc

Martha Solonche

New York, NY 10024
Patient Consult

David R. Spriggs, MD

Memorial Sloan-Kettering Cancer Ctr
New York, NY 10021-6007
Med Onc, Pharm

J. Tate Thigpen, MD (co-chair)

Univ. of Miss Sch of Med
Jackson, MS 39216-4505
Med Onc, Hem

Ignace Vergote, MD, PhD

Univ Hosp Leuven
Gynecologic Oncology
Leuven, Belgium
Gyn Onc

Lari Wenzel, PhD

Associate Professor
Center for Health Policy & Research
Univ of California – Irvine
Irvine, CA 92697
PRO Expert

Ovarian Cancer End Points Workshop
April 26, 2006
North Bethesda Marriott – Bethesda, MD

Panelists and Representatives

FDA Panelists

Lee Pai-Scherf, MD

Medical Officer, Division of Biologic
Oncology Products (DBOP)
Office of Oncology Drug Products (OODP)
Center for Drug Evaluation & Research
(CDER)
Silver Spring, MD 20993-0002

Richard Pazdur, MD (Co-chair)

Director, OODP, CDER
Silver Spring, MD 20993-0002

Karen Weiss, MD

Deputy Director, OODP, CDER
Silver Spring, MD 20993-0002

For CA-125 discussion:

Robert L. Becker, Jr., MD, PhD

Director, Division of Immunology &
Hematology Devices (DIHD)
Office of In Vitro Diagnostic Device
Evaluation & Safety (OIVD)
Center for Devices and Radiological
Health (CDRH)
Rockville, MD 20850

For PRO discussion:

Laurie B. Burke, RPh, MPH

Director, Study Endpoints and Label
Development Team (SEALD)
Office of New Drugs (OND), CDER
Silver Spring, MD 20993-0002

NCI Panelist:

For Biomarker & Endpoint Research Priorities

Edward L. Trimble, MD, MPH

Head, Gynecologic Cancer Therapeutics &
Quality of Cancer Care Therapeutics
Clinical Investigations Branch (CIB)
Cancer Therapy Evaluation Program (CTEP)
Division of Cancer Treatment and
Diagnosis (DCTD)
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Bethesda, MD 20892-7436

FDA Representatives

Peter Bross, MD

Team Leader, Division of Clinical Evaluation
& Pharmacology/Toxicology (DCEPT)
Office of Cellular, Tissue, and Gene
Therapies (OCTGT)
Center for Biologics Evaluation and
Research (CBER)
Rockville, MD 20850

Aloka G. Chakravarty, PhD

Director, Division of Biometrics V
Office of Biostatistics
Office of Pharmacoepidemiology & Statistical
Science (OPSS), CDER
Silver Spring, MD 20993-0002

Julia Corrado, MD

Medical Officer, Obstetrics & Gynecology
Devices Branch (OGDB)
Division of Reproductive, Abdominal & Rad
Devices
Office of Device Evaluation (ODE), CDRH
Rockville, MD 20850

Robert Justice, MD

Acting Director, Division of Drug Oncology
Products (DDOP), OODP, CDER
Silver Spring, MD 20993-0002

Patricia Keegan, MD

Director, DBOP, OODP, CDER
Silver Spring, MD 20993-0002